CPHI
Income statement / Annual
Last year (2024), China Pharma Holdings, Inc.'s total revenue was $4.53 M,
a decrease of 35.41% from the previous year.
In 2024, China Pharma Holdings, Inc.'s net income was -$4.74 M.
See China Pharma Holdings, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$4.53 M |
$7.01 M |
$8.10 M |
$9.64 M |
$10.87 M |
$10.92 M |
$12.33 M |
$13.21 M |
$15.57 M |
$20.35 M |
| Cost of Revenue |
$6.51 M
|
$7.29 M
|
$8.60 M
|
$9.29 M
|
$8.91 M
|
$9.44 M
|
$10.36 M
|
$10.74 M
|
$12.35 M
|
$18.89 M
|
| Gross Profit |
-$1.99 M
|
-$281.09 K
|
-$493.92 K
|
$349.27 K
|
$1.95 M
|
$1.48 M
|
$1.97 M
|
$2.47 M
|
$3.22 M
|
$1.46 M
|
| Gross Profit Ratio |
-0.44
|
-0.04
|
-0.06
|
0.04
|
0.18
|
0.14
|
0.16
|
0.19
|
0.21
|
0.07
|
| Research and Development Expenses |
$283.94 K
|
$240.08 K
|
$185.86 K
|
$318.96 K
|
$377.96 K
|
$229.64 K
|
$172.38 K
|
$90.47 K
|
$365.97 K
|
$961.90 K
|
| General & Administrative Expenses |
$1.78 M
|
$1.47 M
|
$1.89 M
|
$1.65 M
|
$1.82 M
|
$2.29 M
|
$1.95 M
|
$2.02 M
|
$2.27 M
|
$1.90 M
|
| Selling & Marketing Expenses |
$528.82 K
|
$780.33 K
|
$1.07 M
|
$1.50 M
|
$2.22 M
|
$2.35 M
|
$3.22 M
|
$3.46 M
|
$4.04 M
|
$4.29 M
|
| Selling, General & Administrative Expenses |
$2.31 M
|
$2.25 M
|
$2.96 M
|
$3.15 M
|
$4.04 M
|
$4.64 M
|
$5.17 M
|
$5.48 M
|
$6.30 M
|
$6.19 M
|
| Other Expenses |
$5.70 K
|
-$15.76 K
|
-$93.85 K
|
-$255.22 K
|
$115.19 K
|
$0.00
|
$0.00
|
$4.83 T
|
$0.00
|
$0.00
|
| Operating Expenses |
$2.60 M
|
$2.47 M
|
$3.06 M
|
$3.21 M
|
$4.53 M
|
$4.87 M
|
-$12.42 M
|
-$21.15 M
|
-$11.37 M
|
-$15.76 M
|
| Cost And Expenses |
$9.12 M
|
$9.76 M
|
$11.65 M
|
$12.50 M
|
$13.44 M
|
$14.31 M
|
-$2.07 M
|
-$10.40 M
|
$978.03 K
|
$3.12 M
|
| Interest Income |
$6.64 K
|
$6.60 K
|
$10.76 K
|
$3.04 K
|
$5.68 K
|
$27.53 K
|
$38.52 K
|
$64.41 K
|
$130.58 K
|
$119.93 K
|
| Interest Expense |
$154.14 K
|
$333.60 K
|
$434.62 K
|
$542.00 K
|
$294.16 K
|
$321.72 K
|
$451.26 K
|
$539.33 K
|
$849.56 K
|
$1.17 M
|
| Depreciation & Amortization |
$2.62 M
|
$2.75 M
|
$2.70 M
|
$3.09 M
|
$2.68 M
|
$2.93 M
|
$3.26 M
|
$3.29 M
|
$3.08 M
|
-$3.60 M
|
| EBITDA |
-$1.96 M |
$8.44 K |
-$837.69 K |
$230.35 K |
$106.85 K |
-$17.45 M |
-$7.15 M |
-$15.32 M |
-$4.95 M |
-$10.58 M |
| EBITDA Ratio |
-0.43
|
0
|
-0.1
|
0.02
|
0.01
|
-1.6
|
-0.58
|
-1.16
|
-0.32
|
-0.52
|
| Operating Income Ratio |
-1.01
|
-0.39
|
-0.44
|
-0.3
|
-0.24
|
-0.31
|
-0.32
|
-0.34
|
-0.27
|
-0.7
|
| Total Other Income/Expenses Net |
-$147.50 K
|
-$327.00 K
|
-$423.86 K
|
-$538.97 K
|
-$288.48 K
|
-$17.31 M
|
-$6.89 M
|
-$14.66 M
|
-$4.68 M
|
-$1.15 M
|
| Income Before Tax |
-$4.74 M
|
-$3.08 M
|
-$3.97 M
|
-$3.40 M
|
-$2.87 M
|
-$20.70 M
|
-$10.86 M
|
-$19.15 M
|
-$8.87 M
|
-$15.35 M
|
| Income Before Tax Ratio |
-1.05
|
-0.44
|
-0.49
|
-0.35
|
-0.26
|
-1.9
|
-0.88
|
-1.45
|
-0.57
|
-0.75
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$109.99 K
|
$122.63 K
|
$308.18 K
|
$60.44 K
|
| Net Income |
-$4.74 M
|
-$3.08 M
|
-$3.97 M
|
-$3.40 M
|
-$2.87 M
|
-$20.70 M
|
-$10.75 M
|
-$19.28 M
|
-$9.18 M
|
-$15.41 M
|
| Net Income Ratio |
-1.05
|
-0.44
|
-0.49
|
-0.35
|
-0.26
|
-1.9
|
-0.87
|
-1.46
|
-0.59
|
-0.76
|
| EPS |
-0.27 |
-0.29 |
-1.94 |
-0.85 |
-0.72 |
-4.82 |
-2.47 |
-4.42 |
-2.11 |
-3.54 |
| EPS Diluted |
-0.27 |
-0.29 |
-1.94 |
-0.85 |
-0.72 |
-4.82 |
-2.47 |
-4.42 |
-2.11 |
-3.54 |
| Weighted Average Shares Out |
$17.46 M
|
$10.60 M
|
$5.26 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
| Weighted Average Shares Out Diluted |
$17.46 M
|
$10.60 M
|
$5.26 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
$4.61 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
